This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Proof Of RNAi In Man Strengthens Leadership Position Of Tekmira's LNP Delivery Technology

VANCOUVER, British Columbia, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided the following comment on Alnylam Pharmaceuticals, Inc.'s recently presented data from a Phase 1 human clinical trial for ALN-VSP showing that analysis of human tissue samples demonstrated proof of RNAi in man. ALN-VSP utilizes Tekmira's LNP technology, the only RNAi delivery technology supporting multiple clinical candidates being advanced by Tekmira and its partners in multiple disease indications.

Dr. Mark J. Murray, Tekmira's President and CEO, said, "Last week, Tekmira's partner Alnylam presented clinical data from patients with advanced solid tumors with liver involvement treated with ALN-VSP, which demonstrated RNAi activity in humans. This was an important accomplishment by Alnylam and an exciting event for Tekmira, as it confirms that our LNP technology enables bona fide RNAi activity in man. Tekmira's LNP technology has been established as the leading RNAi delivery technology based on both the number of product candidates being advanced and the breadth of therapeutic indications it underpins."

"Human proof-of-concept is an important advancement in the field of RNAi drug development. At Tekmira, we intend to build on this momentum in 2011 with clinical data of our own as well as new partnering relationships. We believe the future is extremely promising for the field of RNAi therapeutics and we remain focused on advancing our therapeutic pipeline and supporting our partners, which depend on our LNP technology to advance their own clinical programs."

"Internally, we are accelerating our discovery efforts and expect to be in a position to advance multiple product candidates over the next few years. We will also continue to build upon our leadership position in delivery as we make advancements in LNP potency and tolerability as well as targeting new disease sites," added Dr. Murray.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs